Cellular redox dysfunction in the development of cardiovascular diseases

Biochimica et Biophysica Acta - General Subjects

Volumn 1861, Issue 11, 2017, Pages 2822-2829

  Kanaan, Georges N ^a   Harper, Mary Ellen ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Cardiac pathologies; Glutathione; Heart; Mitochondria; Oxidative phosphorylation; Oxidative stress; Reactive oxygen species; Redox

Indexed keywords

ADENOSINE TRIPHOSPHATE; DYNAMIN I; GLUTATHIONE; HIGH DENSITY LIPOPROTEIN; HYPOXIA INDUCIBLE FACTOR 1; LOW DENSITY LIPOPROTEIN; MITOFUSIN 1; MITOFUSIN 2; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SIRTUIN 6; THIOREDOXIN; ANTIOXIDANT; FATTY ACID; HYDROGEN PEROXIDE; NITRIC OXIDE; OXYGEN;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL DAMAGE; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; FATTY ACID OXIDATION; GLUCOSE METABOLISM; HEART FAILURE; HEART MITOCHONDRION; HUMAN; HYPERTENSION; HYPERTROPHY; MITOCHONDRIAL DYNAMICS; MITOPHAGY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REDOX STRESS; REPERFUSION INJURY; REVIEW; ENERGY METABOLISM; GENETICS; METABOLISM; MITOCHONDRION; OXIDATION REDUCTION REACTION; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTIOXIDANTS; CARDIOVASCULAR DISEASES; ENERGY METABOLISM; FATTY ACIDS; HUMANS; HYDROGEN PEROXIDE; MITOCHONDRIA; NITRIC OXIDE; OXIDATION-REDUCTION; OXIDATIVE STRESS; OXYGEN; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 85027287623     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2017.07.027     Document Type: Review

References (118)

1. Neubauer, S., The failing heart—an engine out of fuel. N. Engl. J. Med. 356:11 (2007), 1140–1151, 10.1056/NEJMra063052.
2. Moreno-Loshuertos, R., Enríquez, J.A., Respiratory supercomplexes and the functional segmentation of the CoQ pool. Free Radic. Biol. Med. 100 (2016), 5–13, 10.1016/j.freeradbiomed.2016.04.018.
3. 2 + and ATPase additions on isolated porcine heart mitochondria. Cell Calcium 30:1 (2001), 19–27, 10.1054/ceca.2001.0211.
4. Ong, S.-B., Kalkhoran, S.B., Cabrera-Fuentes, H.A., Hausenloy, D.J., Mitochondrial fusion and fission proteins as novel therapeutic targets for treating cardiovascular disease. Eur. J. Pharmacol. 763:Pt A (2015), 104–114, 10.1016/j.ejphar.2015.04.056.
5. Disatnik, M.-H., Ferreira, J.C.B., Campos, J.C., Gomes, K.S., Dourado, P.M.M., Qi, X., Mochly-Rosen, D., Acute inhibition of excessive mitochondrial fission after myocardial infarction prevents long-term cardiac dysfunction. J. Am. Heart Assoc., 2(5), 2013, e000461, 10.1161/JAHA.113.000461.
6. Dorn, G.W., Parkin-dependent mitophagy in the heart. J. Mol. Cell. Cardiol. 95 (2016), 42–49, 10.1016/j.yjmcc.2015.11.023.
7. Köhler, A.C., Sag, C.M., Maier, L.S., Reactive oxygen species and excitation-contraction coupling in the context of cardiac pathology. J. Mol. Cell. Cardiol. 73 (2014), 92–102, 10.1016/j.yjmcc.2014.03.001.
8. Walters, J.W., Amos, D., Ray, K., Santanam, N., Mitochondrial redox status as a target for cardiovascular disease. Curr. Opin. Pharmacol. 27 (2016), 50–55, 10.1016/j.coph.2016.01.006.
9. Dongworth, R.K., Hall, A.R., Burke, N., Hausenloy, D.J., Targeting mitochondria for cardioprotection: examining the benefit for patients. Futur. Cardiol. 10:2 (2014), 255–272, 10.2217/fca.14.6.
10. Schaper, J., Meiser, E., Stämmler, G., Ultrastructural morphometric analysis of myocardium from dogs, rats, hamsters, mice, and from human hearts. Circ. Res. 56:3 (1985), 377–391.
11. Stanley, W.C., Recchia, F.A., Lopaschuk, G.D., Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 85:3 (2005), 1093–1129, 10.1152/physrev.00006.2004.
12. Rosca, M.G., Hoppel, C.L., Mitochondria in heart failure. Cardiovasc. Res. 88:1 (2010), 40–50, 10.1093/cvr/cvq240.
13. Rosca, M.G., Hoppel, C.L., Mitochondrial dysfunction in heart failure. Heart Fail. Rev. 18:5 (2013), 607–622, 10.1007/s10741-012-9340-0.
14. Fillmore, N., Mori, J., Lopaschuk, G.D., Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. Br. J. Pharmacol. 171:8 (2014), 2080–2090, 10.1111/bph.12475.
15. Heather, L.C., Clarke, K., Metabolism, hypoxia and the diabetic heart. J. Mol. Cell. Cardiol. 50:4 (2011), 598–605, 10.1016/j.yjmcc.2011.01.007.
16. Aon, M.A., Tocchetti, C.G., Bhatt, N., Paolocci, N., Cortassa, S., Protective mechanisms of mitochondria and heart function in diabetes. Antioxid. Redox Signal. 22:17 (2015), 1563–1586, 10.1089/ars.2014.6123.
17. Friedman, J.R., Nunnari, J., Mitochondrial form and function. Nature 505:7483 (2014), 335–343, 10.1038/nature12985.
18. Mishra, P., Chan, D.C., Metabolic regulation of mitochondrial dynamics. J. Cell Biol. 212:4 (2016), 379–387, 10.1083/jcb.201511036.
19. Eisner, V., Cupo, R.R., Gao, E., Csordás, G., Slovinsky, W.S., Paillard, M., Hajnóczky, G., Mitochondrial fusion dynamics is robust in the heart and depends on calcium oscillations and contractile activity. Proc. Natl. Acad. Sci. U. S. A. 114:5 (2017), E859–E868, 10.1073/pnas.1617288114.
20. Archer, S.L., Mitochondrial dynamics—mitochondrial fission and fusion in human diseases. N. Engl. J. Med. 369:23 (2013), 2236–2251, 10.1056/NEJMra1215233.
21. Westermann, B., Bioenergetic role of mitochondrial fusion and fission. Biochim. Biophys. Acta 1817:10 (2012), 1833–1838, 10.1016/j.bbabio.2012.02.033.
22. Muller, F., The nature and mechanism of superoxide production by the electron transport chain: its relevance to aging. J. Am. Aging Assoc. 23:4 (2000), 227–253, 10.1007/s11357-000-0022-9.
23. Aon, M.A., Cortassa, S., Marbán, E., O'Rourke, B., Synchronized whole cell oscillations in mitochondrial metabolism triggered by a local release of reactive oxygen species in cardiac myocytes. J. Biol. Chem. 278:45 (2003), 44735–44744, 10.1074/jbc.M302673200.
24. Chen, Q., Vazquez, E.J., Moghaddas, S., Hoppel, C.L., Lesnefsky, E.J., Production of reactive oxygen species by mitochondria: central role of complex III. J. Biol. Chem. 278:38 (2003), 36027–36031, 10.1074/jbc.M304854200.
25. Murphy, M.P., How mitochondria produce reactive oxygen species. Biochem. J. 417:1 (2009), 1–13, 10.1042/BJ20081386.
26. Lambeth, J.D., NOX enzymes and the biology of reactive oxygen. Nat. Rev. Immunol. 4:3 (2004), 181–189, 10.1038/nri1312.
27. Nemoto, S., Takeda, K., Yu, Z.X., Ferrans, V.J., Finkel, T., Role for mitochondrial oxidants as regulators of cellular metabolism. Mol. Cell. Biol. 20:19 (2000), 7311–7318.
28. Sas, K., Robotka, H., Toldi, J., Vécsei, L., Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J. Neurol. Sci. 257:1–2 (2007), 221–239, 10.1016/j.jns.2007.01.033.
29. Zorov, D.B., Juhaszova, M., Sollott, S.J., Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol. Rev. 94:3 (2014), 909–950, 10.1152/physrev.00026.2013.
30. Valko, M., Leibfritz, D., Moncol, J., Cronin, M.T.D., Mazur, M., Telser, J., Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 39:1 (2007), 44–84, 10.1016/j.biocel.2006.07.001.
31. Gao, L., Laude, K., Cai, H., Mitochondrial pathophysiology, reactive oxygen species, and cardiovascular diseases. Vet. Clin. North Am. Small Anim. Pract. 38:1 (2008), 137–155, 10.1016/j.cvsm.2007.10.004 (vi).
32. Campos, J.C., Gomes, K.M.S., Ferreira, J.C.B., Impact of exercise training on redox signaling in cardiovascular diseases. Food Chem. Toxicol. 62 (2013), 107–119, 10.1016/j.fct.2013.08.035.
33. Kalogeris, T., Bao, Y., Korthuis, R.J., Mitochondrial reactive oxygen species: a double edged sword in ischemia/reperfusion vs preconditioning. Redox Biol. 2 (2014), 702–714, 10.1016/j.redox.2014.05.006.
34. Fisher-Wellman, K.H., Lin, C.-T., Ryan, T.E., Reese, L.R., Gilliam, L.A.A., Cathey, B.L., Neufer, P.D., Pyruvate dehydrogenase complex and nicotinamide nucleotide transhydrogenase constitute an energy-consuming redox circuit. Biochem. J. 467:2 (2015), 271–280, 10.1042/BJ20141447.
35. Holmström, K.M., Finkel, T., Cellular mechanisms and physiological consequences of redox-dependent signalling. Nat. Rev. Mol. Cell Biol. 15:6 (2014), 411–421, 10.1038/nrm3801.
36. Kovacic, P., Pozos, R.S., Somanathan, R., Shangari, N., O'Brien, P.J., Mechanism of mitochondrial uncouplers, inhibitors, and toxins: focus on electron transfer, free radicals, and structure-activity relationships. Curr. Med. Chem. 12:22 (2005), 2601–2623.
37. Bartosz, G., Reactive oxygen species: destroyers or messengers?. Biochem. Pharmacol. 77:8 (2009), 1303–1315, 10.1016/j.bcp.2008.11.009.
38. Ray, J.G., Schull, M.J., Kingdom, J.C., Vermeulen, M.J., Heart failure and dysrhythmias after maternal placental syndromes: HAD MPS Study. Heart 98:15 (2012), 1136–1141, 10.1136/heartjnl-2011-301548.
39. Bartz, R.R., Suliman, H.B., Piantadosi, C.A., Redox mechanisms of cardiomyocyte mitochondrial protection. Front. Physiol., 6, 2015, 291, 10.3389/fphys.2015.00291.
40. Cadenas, E., Basic mechanisms of antioxidant activity. BioFactors (Oxf. Engl.) 6:4 (1997), 391–397.
41. Schafer, F.Q., Buettner, G.R., Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic. Biol. Med. 30:11 (2001), 1191–1212.
42. Marí, M., Morales, A., Colell, A., García-Ruiz, C., Fernández-Checa, J.C., Mitochondrial glutathione, a key survival antioxidant. Antioxid. Redox Signal. 11:11 (2009), 2685–2700, 10.1089/ARS.2009.2695.
43. Murphy, M.P., Mitochondrial thiols in antioxidant protection and redox signaling: distinct roles for glutathionylation and other thiol modifications. Antioxid. Redox Signal. 16:6 (2012), 476–495, 10.1089/ars.2011.4289.
44. Fernandez-Checa, J.C., Kaplowitz, N., Hepatic mitochondrial glutathione: transport and role in disease and toxicity. Toxicol. Appl. Pharmacol. 204:3 (2005), 263–273, 10.1016/j.taap.2004.10.001.
45. Lundberg, M., Johansson, C., Chandra, J., Enoksson, M., Jacobsson, G., Ljung, J., Holmgren, A., Cloning and expression of a novel human glutaredoxin (Grx2) with mitochondrial and nuclear isoforms. J. Biol. Chem. 276:28 (2001), 26269–26275, 10.1074/jbc.M011605200.
46. Chen, J., Schenker, S., Henderson, G.I., 4-hydroxynonenal detoxification by mitochondrial glutathione S-transferase is compromised by short-term ethanol consumption in rats. Alcohol. Clin. Exp. Res. 26:8 (2002), 1252–1258, 10.1111/j.1530-0277.2002.tb02664.x.
47. Orrenius, S., Gogvadze, V., Zhivotovsky, B., Mitochondrial oxidative stress: implications for cell death. Annu. Rev. Pharmacol. Toxicol. 47:1 (2007), 143–183, 10.1146/annurev.pharmtox.47.120505.105122.
48. Savaskan, N.E., Ufer, C., Kühn, H., Borchert, A., Molecular biology of glutathione peroxidase 4: from genomic structure to developmental expression and neural function. Biol. Chem. 388:10 (2007), 1007–1017, 10.1515/BC.2007.126.
49. Yant, L.J., Ran, Q., Rao, L., Van Remmen, H., Shibatani, T., Belter, J.G., Prolla, T.A., The selenoprotein GPX4 is essential for mouse development and protects from radiation and oxidative damage insults. Free Radic. Biol. Med. 34:4 (2003), 496–502.
50. Hayes, J.D., Flanagan, J.U., Jowsey, I.R., Glutathione transferases. Annu. Rev. Pharmacol. Toxicol. 45 (2005), 51–88, 10.1146/annurev.pharmtox.45.120403.095857.
51. Herrero, E., Ros, J., [14] Glutaredoxins and oxidative stress defense in yeast. Methods Enzymol. 348 (2002), 136–146, 10.1016/S0076-6879(02)48633-8.
52. Koehler, C.M., Beverly, K., Leverich, E.P., Redox pathways in the mitochondrion. Antioxid. Redox Signal. 8 (2006), 813–822.
53. Pedrajas, J.R., Kosmidou, E., Miranda-Vizuete, A., Gustafsson, J.A., Wright, A.P., Spyrou, G., Identification and functional characterization of a novel mitochondrial thioredoxin system in Saccharomyces cerevisiae. J. Biol. Chem. 274 (1999), 6366–6373.
54. Go, Y.-M., Jones, D.P., Cysteine/cystine redox signaling in cardiovascular disease. Free Radic. Biol. Med. 50:4 (2011), 495–509, 10.1016/j.freeradbiomed.2010.11.029.
55. Madamanchi, N.R., Runge, M.S., Redox signaling in cardiovascular health and disease. Free Radic. Biol. Med. 61 (2013), 473–501, 10.1016/j.freeradbiomed.2013.04.001.
56. Kubes, P., Suzuki, M., Granger, D.N., Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. U. S. A. 88:11 (1991), 4651–4655.
57. Quyyumi, A.A., Dakak, N., Andrews, N.P., Gilligan, D.M., Panza, J.A., Cannon, R.O., Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation 92:3 (1995), 320–326.
58. Ahluwalia, A., Foster, P., Scotland, R.S., McLean, P.G., Mathur, A., Perretti, M., Hobbs, A.J., Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc. Natl. Acad. Sci. U. S. A. 101:5 (2004), 1386–1391, 10.1073/pnas.0304264101.
59. Murry, C.E., Richard, V.J., Reimer, K.A., Jennings, R.B., Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ. Res. 66:4 (1990), 913–931.
60. Liu, Y., Downey, J.M., Ischemic preconditioning protects against infarction in rat heart. Am. J. Phys. 263:4 Pt 2 (1992), H1107–1112.
61. Lasley, R.D., Anderson, G.M., Mentzer, R.M., Ischaemic and hypoxic preconditioning enhance postischaemic recovery of function in the rat heart. Cardiovasc. Res. 27:4 (1993), 565–570.
62. Chen, W., Gabel, S., Steenbergen, C., Murphy, E., A redox-based mechanism for cardioprotection induced by ischemic preconditioning in perfused rat heart. Circ. Res. 77:2 (1995), 424–429.
63. Forbes, R.A., Steenbergen, C., Murphy, E., Diazoxide-induced cardioprotection requires signaling through a redox-sensitive mechanism. Circ. Res. 88:8 (2001), 802–809.
64. Bers, D.M., Cardiac excitation-contraction coupling. Nature 415:6868 (2002), 198–205, 10.1038/415198a.
65. 2 +]i. J. Mol. Cell. Cardiol. 58 (2013), 172–181, 10.1016/j.yjmcc.2012.11.011.
66. Prosser, B.L., Ward, C.W., Lederer, W.J., X-ROS signaling: rapid mechano-chemo transduction in heart. Science (New York, N.Y.) 333:6048 (2011), 1440–1445, 10.1126/science.1202768.
67. Kerr, J.P., Robison, P., Shi, G., Bogush, A.I., Kempema, A.M., Hexum, J.K., Ward, C.W., Detyrosinated microtubules modulate mechanotransduction in heart and skeletal muscle. Nat. Commun., 6, 2015, 8526, 10.1038/ncomms9526.
68. Wende, A.R., Young, M.E., Chatham, J., Zhang, J., Rajasekaran, N.S., Darley-Usmar, V.M., Redox biology and the interface between bioenergetics, autophagy and circadian control of metabolism. Free Radic. Biol. Med. 100 (2016), 94–107, 10.1016/j.freeradbiomed.2016.05.022.
69. Aon, M.A., Cortassa, S., O'Rourke, B., Redox-optimized ROS balance: a unifying hypothesis. Biochim. Biophys. Acta 1797:6–7 (2010), 865–877, 10.1016/j.bbabio.2010.02.016.
70. Cortassa, S., O'Rourke, B., Aon, M.A., Redox-optimized ROS balance and the relationship between mitochondrial respiration and ROS. Biochim. Biophys. Acta 1837:2 (2014), 287–295, 10.1016/j.bbabio.2013.11.007.
71. Hidalgo, C., Donoso, P., Cell signaling. Getting to the heart of mechanotransduction. Science (New York, N.Y.) 333:6048 (2011), 1388–1390, 10.1126/science.1212183.
72. Santos, C.X.C., Anilkumar, N., Zhang, M., Brewer, A.C., Shah, A.M., Redox signaling in cardiac myocytes. Free Radic. Biol. Med. 50:7 (2011), 777–793, 10.1016/j.freeradbiomed.2011.01.003.
73. Schulz, E., Gori, T., Münzel, T., Oxidative stress and endothelial dysfunction in hypertension. Hypertens. Res. 34:6 (2011), 665–673, 10.1038/hr.2011.39.
74. Mügge, A., Elwell, J.H., Peterson, T.E., Hofmeyer, T.G., Heistad, D.D., Harrison, D.G., Chronic treatment with polyethylene-glycolated superoxide dismutase partially restores endothelium-dependent vascular relaxations in cholesterol-fed rabbits. Circ. Res. 69:5 (1991), 1293–1300.
75. Cai, H., Harrison, D.G., Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 87:10 (2000), 840–844.
76. Hein, T.W., Zhang, C., Wang, W., Chang, C.-I., Thengchaisri, N., Kuo, L., Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. FASEB J. 17:15 (2003), 2328–2330, 10.1096/fj.03-0115fje.
77. Zhang, C., Hein, T.W., Wang, W., Miller, M.W., Fossum, T.W., McDonald, M.M., Kuo, L., Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension 44:6 (2004), 935–943, 10.1161/01.HYP.0000146907.82869.f2.
78. White, A.R., Ryoo, S., Li, D., Champion, H.C., Steppan, J., Wang, D., Berkowitz, D.E., Knockdown of arginase I restores NO signaling in the vasculature of old rats. Hypertension 47:2 (2006), 245–251, 10.1161/01.HYP.0000198543.34502.d7.
79. Ryoo, S., Gupta, G., Benjo, A., Lim, H.K., Camara, A., Sikka, G., Berkowitz, D.E., Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ. Res. 102:8 (2008), 923–932, 10.1161/CIRCRESAHA.107.169573.
80. Gioscia-Ryan, R.A., LaRocca, T.J., Sindler, A.L., Zigler, M.C., Murphy, M.P., Seals, D.R., Mitochondria-targeted antioxidant (MitoQ) ameliorates age-related arterial endothelial dysfunction in mice. J. Physiol. 592:12 (2014), 2549–2561, 10.1113/jphysiol.2013.268680.
81. Park, S.-Y., Kwon, O.S., Andtbacka, R.H.I., Hyngstrom, J.R., Reese, V., Murphy, M.P., Richardson, R.S., Age-related endothelial dysfunction in human skeletal muscle feed arteries: the role of free radicals derived from mitochondria in the vasculature. Acta Physiol (Oxf.), 2017, 10.1111/apha.12893.
82. Go, Y.-M., Son, D.J., Park, H., Orr, M., Hao, L., Takabe, W., Jones, D.P., Disturbed flow enhances inflammatory signaling and atherogenesis by increasing thioredoxin-1 level in endothelial cell nuclei. PLoS One, 9(9), 2014, e108346, 10.1371/journal.pone.0108346.
83. Romero, M.J., Platt, D.H., Tawfik, H.E., Labazi, M., El-Remessy, A.B., Bartoli, M., Caldwell, R.W., Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ. Res. 102:1 (2008), 95–102, 10.1161/CIRCRESAHA.107.155028.
84. Vanhoutte, P.M., Endothelial control of vasomotor function: from health to coronary disease. Circ. J. 67:7 (2003), 572–575.
85. Madamanchi, N.R., Vendrov, A., Runge, M.S., Oxidative stress and vascular disease. Arterioscler. Thromb. Vasc. Biol. 25:1 (2005), 29–38, 10.1161/01.ATV.0000150649.39934.13.
86. Hulsmans, M., Holvoet, P., The vicious circle between oxidative stress and inflammation in atherosclerosis. J. Cell. Mol. Med. 14:1–2 (2010), 70–78, 10.1111/j.1582-4934.2009.00978.x.
87. Stocker, R., Keaney, J.F., Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84:4 (2004), 1381–1478, 10.1152/physrev.00047.2003.
88. Bergt, C., Pennathur, S., Fu, X., Byun, J., O'Brien, K., McDonald, T.O., Heinecke, J.W., The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc. Natl. Acad. Sci. U. S. A. 101:35 (2004), 13032–13037, 10.1073/pnas.0405292101.
89. Shao, B., Oda, M.N., Bergt, C., Fu, X., Green, P.S., Brot, N., Heinecke, J.W., Myeloperoxidase impairs ABCA1-dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I. J. Biol. Chem. 281:14 (2006), 9001–9004, 10.1074/jbc.C600011200.
90. Peshavariya, H., Dusting, G.J., Di Bartolo, B., Rye, K.-A., Barter, P.J., Jiang, F., Reconstituted high-density lipoprotein suppresses leukocyte NADPH oxidase activation by disrupting lipid rafts. Free Radic. Res. 43:8 (2009), 772–782, 10.1080/10715760903045304.
91. Undurti, A., Huang, Y., Lupica, J.A., Smith, J.D., DiDonato, J.A., Hazen, S.L., Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J. Biol. Chem. 284:45 (2009), 30825–30835, 10.1074/jbc.M109.047605.
92. Sorescu, D., Weiss, D., Lassègue, B., Clempus, R.E., Szöcs, K., Sorescu, G.P., Griendling, K.K., Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 105:12 (2002), 1429–1435.
93. Vendrov, A.E., Madamanchi, N.R., Niu, X.-L., Molnar, K.C., Runge, M., Szyndralewiez, C., Runge, M.S., NADPH oxidases regulate CD44 and hyaluronic acid expression in thrombin-treated vascular smooth muscle cells and in atherosclerosis. J. Biol. Chem. 285:34 (2010), 26545–26557, 10.1074/jbc.M110.143917.
94. Fenyo, I.M., Florea, I.C., Raicu, M., Manea, A., Tyrphostin AG490 reduces NAPDH oxidase activity and expression in the aorta of hypercholesterolemic apolipoprotein E-deficient mice. Vasc. Pharmacol. 54:3–6 (2011), 100–106, 10.1016/j.vph.2011.03.006.
95. Patel, R.S., Al Mheid, I., Morris, A.A., Ahmed, Y., Kavtaradze, N., Ali, S., Quyyumi, A.A., Oxidative stress is associated with impaired arterial elasticity. Atherosclerosis 218:1 (2011), 90–95, 10.1016/j.atherosclerosis.2011.04.033.
96. Park, S., Lakatta, E.G., Role of inflammation in the pathogenesis of arterial stiffness. Yonsei Med. J. 53:2 (2012), 258–261, 10.3349/ymj.2012.53.2.258.
97. Nakazono, K., Watanabe, N., Matsuno, K., Sasaki, J., Sato, T., Inoue, M., Does superoxide underlie the pathogenesis of hypertension?. Proc. Natl. Acad. Sci. U. S. A. 88:22 (1991), 10045–10048.
98. Zimmerman, M.C., Lazartigues, E., Sharma, R.V., Davisson, R.L., Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ. Res. 95:2 (2004), 210–216, 10.1161/01.RES.0000135483.12297.e4.
99. Peterson, J.R., Burmeister, M.A., Tian, X., Zhou, Y., Guruju, M.R., Stupinski, J.A., Davisson, R.L., Genetic silencing of Nox2 and Nox4 reveals differential roles of these NADPH oxidase homologues in the vasopressor and dipsogenic effects of brain angiotensin II. Hypertension 54:5 (2009), 1106–1114, 10.1161/HYPERTENSIONAHA.109.140087.
100. Dikalova, A.E., Bikineyeva, A.T., Budzyn, K., Nazarewicz, R.R., McCann, L., Lewis, W., Dikalov, S.I., Therapeutic targeting of mitochondrial superoxide in hypertension. Circ. Res. 107:1 (2010), 106–116, 10.1161/CIRCRESAHA.109.214601.
101. Dikalova, A.E., Góngora, M.C., Harrison, D.G., Lambeth, J.D., Dikalov, S., Griendling, K.K., Upregulation of Nox1 in vascular smooth muscle leads to impaired endothelium-dependent relaxation via eNOS uncoupling. Am. J. Physiol. Heart Circ. Physiol. 299:3 (2010), H673–679, 10.1152/ajpheart.00242.2010.
102. Claycomb, W.C., Cardiac muscle cell proliferation and cell differentiation in vivo and in vitro. Adv. Exp. Med. Biol. 161 (1983), 249–265.
103. Abate, C., Patel, L., Rauscher, F.J., Curran, T., Redox regulation of Fos and Jun DNA-binding activity in vitro. Science (New York, N.Y.) 249:4973 (1990), 1157–1161.
104. Pimentel, D.R., Amin, J.K., Xiao, L., Miller, T., Viereck, J., Oliver-Krasinski, J., Sawyer, D.B., Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes. Circ. Res. 89:5 (2001), 453–460.
105. Yamamoto, M., Yang, G., Hong, C., Liu, J., Holle, E., Yu, X., Sadoshima, J., Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. J. Clin. Invest. 112:9 (2003), 1395–1406, 10.1172/JCI17700.
106. Ago, T., Liu, T., Zhai, P., Chen, W., Li, H., Molkentin, J.D., Sadoshima, J., A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell 133:6 (2008), 978–993, 10.1016/j.cell.2008.04.041.
107. Doerries, C., Grote, K., Hilfiker-Kleiner, D., Luchtefeld, M., Schaefer, A., Holland, S.M., Landmesser, U., Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ. Res. 100:6 (2007), 894–903, 10.1161/01.RES.0000261657.76299.ff.
108. Ago, T., Kuroda, J., Pain, J., Fu, C., Li, H., Sadoshima, J., Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. Circ. Res. 106:7 (2010), 1253–1264, 10.1161/CIRCRESAHA.109.213116.
109. Ekelund, U.E., Harrison, R.W., Shokek, O., Thakkar, R.N., Tunin, R.S., Senzaki, H., Hare, J.M., Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ. Res. 85:5 (1999), 437–445.
110. Cappola, T.P., Kass, D.A., Nelson, G.S., Berger, R.D., Rosas, G.O., Kobeissi, Z.A., Hare, J.M., Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 104:20 (2001), 2407–2411.
111. Murphy, E., Steenbergen, C., Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol. Rev. 88:2 (2008), 581–609, 10.1152/physrev.00024.2007.
112. Forgione, M.A., Cap, A., Liao, R., Moldovan, N.I., Eberhardt, R.T., Lim, C.C., Loscalzo, J., Heterozygous cellular glutathione peroxidase deficiency in the mouse: abnormalities in vascular and cardiac function and structure. Circulation 106:9 (2002), 1154–1158.
113. Yoshioka, J., Chutkow, W.A., Lee, S., Kim, J.B., Yan, J., Tian, R., Lee, R.T., Deletion of thioredoxin-interacting protein in mice impairs mitochondrial function but protects the myocardium from ischemia-reperfusion injury. J. Clin. Invest. 122:1 (2012), 267–279, 10.1172/JCI44927.
114. Chandel, N.S., Maltepe, E., Goldwasser, E., Mathieu, C.E., Simon, M.C., Schumacker, P.T., Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc. Natl. Acad. Sci. U. S. A. 95:20 (1998), 11715–11720.
115. 2 sensing. J. Biol. Chem. 275:33 (2000), 25130–25138, 10.1074/jbc.M001914200.
116. Agani, F.H., Pichiule, P., Chavez, J.C., LaManna, J.C., The role of mitochondria in the regulation of hypoxia-inducible factor 1 expression during hypoxia. J. Biol. Chem. 275:46 (2000), 35863–35867, 10.1074/jbc.M005643200.
117. Giordano, F.J., Oxygen, oxidative stress, hypoxia, and heart failure. J. Clin. Invest. 115:3 (2005), 500–508, 10.1172/JCI24408.
118. Wang, X.-X., Wang, X.-L., Tong, M., Gan, L., Chen, H., Wu, S., Jiang, W., SIRT6 protects cardiomyocytes against ischemia/reperfusion injury by augmenting FoxO3α-dependent antioxidant defense mechanisms. Basic Res. Cardiol., 111(2), 2016, 13, 10.1007/s00395-016-0531-z.